Edition:
Deutschland

Chugai Pharmaceutical Co Ltd (4519.T)

4519.T on Tokyo Stock Exchange

8,160JPY
20 Sep 2019
Change (% chg)

¥140 (+1.75%)
Prev Close
¥8,020
Open
¥8,100
Day's High
¥8,260
Day's Low
¥8,100
Volume
815,700
Avg. Vol
671,898
52-wk High
¥8,260
52-wk Low
¥6,170

About

CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Domestic segment is engaged in the sale of pharmaceutical products manufactured by the Company through its nationwide appointed stores. This segment is also involved in the research, development, transportation and storage of pharmaceutical products, as... (more)

Buy/Sell

Sell Hold Buy
2.73 Mean rating from 11 analysts

Overall

Beta: 0.83
Market Cap(Mil.): ¥4,298,388.00
Shares Outstanding(Mil.): 559.69
Dividend: 48.00
Yield (%): 1.16

Japan stocks up for seventh trading session on rising yields, falling yen

TOKYO, Sept 11 Japanese stocks rose to a six-week high on Wednesday as bank shares extended recent gains thanks to rising bond yields, while major exporters reaped the rewards of a faltering yen.

BRIEF-Chugai Pharmaceutical Says Tecentriq Approved As Lung Cancer Treatment In Japan

* CHUGAI PHARMACEUTICAL - TECENTRIQ RECEIVES APPROVAL FOR ADDITIONAL INDICATION OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER FROM JAPAN'S MHLW

Photo

Japan's polarised stock market leaves few options for investors

TOKYO The gap in valuations of Japanese shares is at its widest since the dot-com crisis two decades ago and will likely stay that way until global trade tensions ease, analysts say.

Photo

Japan's polarized stock market leaves few options for investors

TOKYO The gap in valuations of Japanese shares is at its widest since the dot-com crisis two decades ago and will likely stay that way until global trade tensions ease, analysts say.

GRAPHIC-Japan's polarised stock market leaves few options for investors

* Japan stocks most polarised since dot-com bubble in 1999-2000

BRIEF-Chugai Obtains Approval Of FoundationOne CDx Cancer Genomic Profile As A Companion Diagnostic For Rozlytrek

* CHUGAI PHARMACEUTICAL - CHUGAI OBTAINS APPROVAL OF FOUNDATIONONE CDX CANCER GENOMIC PROFILE AS A COMPANION DIAGNOSTIC FOR ROZLYTREK Source text for Eikon: Further company coverage:

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.08%
Rohstoffe -0.55%
Industrie -0.61%
Konjunktur abhängige Waren & Dienstleistungen -0.28%
Konjunktur unabhängige Waren & Dienstleistungen -0.19%
Finanzindustrie +0.60%
Pharma -0.87%
Technologie +0.65%
Telekommunikation +0.19%